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Abstract 
This study sought to identify novel CD8+ T cell homing markers by studying acute graft versus host 
disease (aGvHD), typically involving increased T cell homing to the skin and gut. FACS-sorted skin-
homing (CD8β+/CLA+), gut-homing (CD8β+/integrinβ7+), and reference (CD8β+/CLA-/integrinβ7-) T 
cells were compared in patients affected by cutaneous and/or gastrointestinal aGVHD. Microarray 
analysis, Q-PCR and flow cytometry revealed increased expression of peptidase inhibitor 16 (PI16) in 
skin-homing CD8+ T cells. Robust association of PI16 with skin-homing was confirmed in all types of 
aGvHD and in healthy controls, too. PI16 was not observed on CLA+ leukocytes other than T cells. 
Induction of PI16 expression on skin-homing T cells occurred independently of vitamin D3. Among 
skin-homing T cells, PI16 expression was most pronounced in memory-like 
CD45RO+/CD127+/CD25+/CD69-/granzyme-B- cells. PI16 was confined to the plasma membrane, 
was GPI-anchored, and was lost upon re-stimulation of memory CD8+ T cells. Loss of PI16 occurred 
by down-regulation of PI16 transcription, and not by PLC- or ACE-mediated shedding, or by protein 
recycling. Inhibitor screening and pull-down experiments confirmed that PI16 inhibits cathepsin-K, 
but may not bind to other skin proteases.   
These data link PI16 to skin-homing CD8+ T cells, and raise the possibility that PI16 may regulate 
cutaneous cathepsin-K.        
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Introduction 
Precise regulation of CD8+ T cell homing to distinct tissues is a prerequisite for mounting immune 
responses against pathogens that have narrow tissue tropism. It is well established that regulation of 
T cell homing utilizes complex regulatory circuits involving unique combinations of chemokines and 
adhesion molecules, each identifying different tissues for circulating T cells. Homing is heavily 
implicated in the maintenance of immunity against antigen challenge occurring in different 
anatomical compartments, especially in barrier tissues, such as the gut and the skin [1]. On the other 
hand, T cell homing to distinct anatomical compartments is also involved in the development of 
several immunologic disorders or adverse immune reactions restricted to given tissues or organs. 
This has been demonstrated in multiple animal models and human clinical studies, among others in 
ulcerative colitis (UC) [2, 3], multiple sclerosis (MS) [4, 5], Crohn’s disease (CD) [6, 7], and has also 
been suggested to be involved in acute graft versus host disease (aGvHD). We believe that aGvHD is 
of particular interest in terms of CD8+ T cell homing to the gut and skin, for several reasons.  
Acute GvHD is one of the most frequent, potentially fatal, short-term adverse event of allogeneic 
hematopoietic stem cell transplantation (aHSCT) [8]. The disease is typically associated with massive, 
graft-mediated cytotoxic tissue damage, characteristically restricted to a limited set of organs, 
typically to the skin and the gut [9, 10]. Notably, some patients suffer from either cutaneous or 
gastrointestinal aGvHD, while others display both manifestations simultaneously. Tissue damage in 
both cutaneous and gastrointestinal aGvHD occurs upon invasion of the skin and gut by CD8+ T cells 
[9] displaying canonical skin-homing (CLA+) and gut-homing integrinβ7+ (ITGβ4β7+) phenotypes, 
respectively [11, 12]. It has been shown that rapid shifts in the numbers of these activated subsets in 
the blood of aHSCT patients precede the two forms of the disease, and hence may be of diagnostic 
and prognostic value [11-13]. Furthermore, proof of concept studies showed that blockade of CD8+ 
T cell homing pathways may alleviate respective tissue damage in mouse models of aGVHD [14, 15]. 
Indeed, current phase 1 and phase 2 clinical trials with two monoclonal antibodies, vedolizumab and 
 This article is protected by copyright. All rights reserved. 4 
natalizumab, targeting ITGβ4 or ITGβ4β7, approved for the treatment of UC/CD and CD/MS, 
respectively, are currently exploring whether the same approach may work for the treatment of  
gastrointestinal aGVHD in humans, as well [16, 17]. Although less well documented, there is some 
evidence that the homing preferences of activated CD4+ Th and Treg cells are also altered in aGvHD. 
Activated CD4+ Th cells become enriched in damaged organs [18]. In contrast, Treg cells home to 
tissues affected by aGvHD in diminished numbers [19, 20]. 
Taken together, aHSCT patients diagnosed with cutaneous and/or GI aGvHD provide a unique 
opportunity for the in-depth comparison of naturally activated human CD8+ T cells homing to the 
gut and skin, for several reasons: i) in aGvHD, CD8+ T cells home to both the skin and the gut, 
enabling a direct comparison of the two cell types in the same human disease, without the skewing 
effect of different disease states, ii) these phenomena may occur simultaneously, enabling the 
comparison of these cells within the same host iii) CD8+ T cells actively home to these organs and 
are not only attracted by local inflammation iv) full maturation of skin- and gut-homing effector 
CD8+ T cells takes place v) effector mechanisms mediated by skin- and gut-homing CD8+ T cells are 
fundamental to the disease process. 
In this study, we compared skin-and gut-homing CD8+ T cells of aGvHD patients by gene expression 
profiling, flow cytometry, and functional bioassays, and confirmed our findings on CD8+ T cells of 
healthy blood donors, as well. We propose that a novel marker, peptidase inhibitor 16 (PI16), is 
associated with the skin-homing CD8+ T cell subset in both aGVHD patients, and healthy individuals. 
Based on these results we propose that PI16 is linked to human skin-homing T cells in both 
inflammatory and steady-state conditions.  
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Results 
Skin-homing CD8+ T cells overexpress PI16 mRNA in patients affected by aGvHD 
Skin- and gut-homing CD8+ T cell subsets were isolated from four groups of aHSCT patients 
developing i) cutaneous aGvHD, ii) gastrointestinal aGvHD, iii) both cutaneous and GI aGvHD 
simultaneously, or iv) none (see Supplementary table 1 for detailed patient information). PBMCs of 
aHSCT patients were sorted into skin-homing Ly/LIVE/DEAD®-/CD8β+/CLA+, gut-homing 
Ly/LIVE/DEAD®-/CD8β+/ITGβ7+, and reference Ly/LIVE/DEAD®-/CD8β+/CLA-/ITGβ7- cytotoxic T cell 
subsets by three-way FACS sorting (Fig 1A). Next, skin-homing, gut-homing and reference CD8+ T 
cells were analyzed by comparative gene expression profiling. Transcriptome analysis revealed 62 
genes differentially expressed between the three CTL subsets (Fig 1B, Two-Way RM ANOVA with 
FDR<0.01, see Supplementary table 2 for detailed results). As gene set enrichment analysis was 
unable to identify known gene sets differentially expressed depending on CTL homing preferences 
(p>0.05), we next set out to analyze individual genes. Among the most significant differences, we 
selected peptidase inhibitor 16 (PI16) for further analysis (Fig 1B, marked with asterisk to the right) 
based on others’ earlier publications [21, 22]. 
PI16 expression is a hallmark feature of skin homing CD8+ T cells regardless of organ involvement 
in aGvHD 
Microarray data suggested that PI16 mRNA showed >9 times higher expression in skin-homing 
CD8β+/CLA+ T cells than in gut-homing, or reference CTLs of aHSCT patients (Fig 2B, One-Way RM 
ANOVA, p<0.0001). We analyzed whether this phenomenon was restricted to any of the four patient 
groups, i.e. linked to any given type of CTL-mediated organ damage in aGvHD, or GvHD in general 
(Fig 2B). We found that overexpression of PI16 by skin-homing CLA+ CD8+ T cells occurred in all four 
patient groups (Fig 2B, Two-Way RM ANOVA, p<0.0001) regardless of the type of organ involvement 
in aGVHD (p>0.05). In addition, the data suggested that PI16 overexpression was not restricted to 
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aGVHD, as aHSCT patients with no aGvHD also displayed increased expression of PI16 in skin-homing 
CD8+ T cells. These results were also confirmed by Q-PCR (Fig 2C, 2D Two-Way RM ANOVA, 
p<0.0001). Flow cytometry also confirmed that PI16 protein positive cells were enriched in the CLA+ 
subset (on average 10.9-times) compared with reference CTLs (Fig 2E-G). Furthermore, PI16+ cells 
were significantly more frequent (on average 5.2-times) among skin-homing than among gut-homing 
CD8+ T cells (Fig 2E, Two-Way RM ANOVA, p=0.0004). This observed pattern held true in all patient 
groups regardless of the type of organ involvement (Fig 2F, Two-Way RM ANOVA, p=0.9388), which 
is in line with the RNA data. Again, observed organ damage did not appear to have an influence on 
the pattern of PI16 expression (Fig 2F, Two-Way RM ANOVA, p=0.9204), even if, in the cutaneous 
aGvHD group, between-subset comparisons did not reach formal significance (Fig 2F, p=0.2266, 
p=0.4859, respectively). These observations conclusively suggested that PI16 is associated with skin-
homing CD8+ T cells, the expression of which may be largely independent of the development of 
aGvHD, or the exact type of organ involvement in aGvHD.  
Robust association of PI16 protein with skin-homing CD8+ T cells in both health and disease  
As the expression of PI16 appeared to be independent of aGvHD, we next went on to test whether 
aHSCT was required at all for the induction of PI16 expression on skin homing T cells. To this end, we 
analyzed skin-homing, gut homing and reference CTLs of healthy blood donors in a similar fashion. 
We found PI16 expression patterns matching those observed in aHSCT, with even more pronounced 
differences of PI16 expression between cell subsets among healthy individuals compared with aHSCT 
patient. On average, 63% of the skin-homing T cells of healthy blood donors stained positive for PI16 
protein; 13.3-times more than gut-homing T cells (4.74%), and 7.5-times more than reference 
(8.43%) CTLs (Fig 3A, Two-Way RM ANOVA, p<0.0001). These data suggested that the presence of 
PI16 on skin homing T cells is a distinctive feature of this subset in both health and disease, i.e. it is 
not restricted to, or induced by either aGvHD or aHSCT. Also, it was apparent that the difference is 
more pronounced among healthy individuals, than in aHSCT patients (irrespective of them being 
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affected by, or remaining free of aGvHD). For these reasons, we used healthy donors for the further 
analysis of PI16.  
PI16 is a marker associated with skin-homing CD8+ T cells but not other CLA+ leukocytes  
Considering that CLA is frequently expressed by a wide variety of leukocytes beside CD8+ T cells, we 
first sought to clarify if PI16 expression is linked to CLA expression, or if it is a restricted feature 
typical to skin-homing T cells. Flow cytometry confirmed that PI16 over-expression was restricted to 
CLA+ T CD8+ and CD4+ T cells, as CLA+ monocytes or NK cells expressing CLA did not display PI16 in 
appreciable numbers (Fig 3B). This suggests that expression of PI16 is not mechanistically linked to 
that of CLA in various leukocytes; but instead, PI16 is specifically linked to skin-homing T cells.  We 
also found that within the skin-homing CD8+ T cell subset, PI16 positive cells were more frequently 
CD45RO+, CD127+, CD25+, CD69-, granzyme-B- cells (Fig 3C), than their PI16 negative counterparts, 
while there was no difference in the case of some other CD8+ T cell markers (IFNγ, CD40L, not 
shown). These data indicate that PI16 production is most intense in memory-like, resting skin-
homing CD8+ T cells and is less characteristic for recently activated effector cytotoxic T cells actively 
producing effector molecules. Finally, we tested if PI16 expression was maintained in skin-homing T 
cells after entering the human skin, like that of CLA[23], or became down-regulated upon entering 
the target organ, like in the case of integrinβ4 on gut-homing T cells [24]. We found that PI16-
expressing CD8+ CLA+ T cells can be found in the healthy human skin (Fig 4). Spatial distribution of 
PI16 in the skin was similar to others’ earlier observations [25]: i.e. weak or absent in the epidermis, 
scattered in the dermis. We found that scattered dermal PI16 positivity showed clear co-localization 
with cutaneous CD8+/CLA+ T cells (Fig 4). 
Skin homing CD8+ T cells display a membrane-bound, GPI-anchored PI16 protein 
PI16 is a protein with largely unknown functions that, originally, was described as a soluble serum 
protein released by prostate cells [26]. However, it has been reported that the protein may appear 
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on the surface of Treg cells [22], and this is also in line with our flow cytometry data. By performing 
confocal microscopy on sorted CD8+ T cells, we found that the majority of PI16 protein in CD8+ T 
cells was indeed confined to the plasma membrane (PM), showing a similar distribution to, but no 
clear co-localization with, CLA (Fig 5A), within the PM. Recently, it has been confirmed that PI16 
protein expressed by murine fibroblasts is GPI-anchored [27]. To test the means of PI16 linkage to 
the PM of human CD8+ T cells, we exposed CD8+ T cells to a bacterial PI-PLC, capable of detaching 
GPI-anchored proteins from the PM. We found that upon exposition of CD8β+/PI16+ T cells to PI-
PLC, PI16+ staining showed a rapid, dose-dependent reduction (Fig 5B), similar to that of CD59, a 
known GPI-anchored protein, but unlike CD8β, which does not have a GPI anchor, and hence 
remained unaffected. These data demonstrate that human skin homing CLA+ T cells express a 
membrane bound, GPI-anchored form of PI16.             
Induction of PI16 occurs independently of canonical pathways imprinting the skin-homing 
phenotype  
We next analyzed whether known mechanisms responsible for imprinting the skin- and gut-homing 
phenotype in activated naïve CD8+ T cells could also invoke or suppress PI16 expression on these 
cells. In two seminal papers, it was shown that exposure of in vitro activated blood CD8+ T cells to 
dendritic cell-released vitamin D (D3) and retinoic acid (RA) was capable of inducing some (although 
not all) skin- and gut homing markers, respectively, in a mutually exclusive fashion [28, 29]. Using 
this approach, we found that although D3 and RA were capable of affecting expression of the skin-
homing markers CLA (Fig 6A, Two-Way RM ANOVA, p=0.0049) and CCR10 on activated CD8+ T cells 
(Fig 6B, Two-Way RM ANOVA, p=0.0015), PI16 remained unaffected by D3 and RA, only reacting on T 
cell activation (Fig 6C). We next tested whether expression of PI16 on skin-homing T cells may be 
induced independently of DC-mediators, e.g. by local epithelia. It has been suggested that skin 
epithelial cells may imprint activated skin-homing T cells to express CLA and CCR8 via soluble 
mediators that reach skin-draining lymph nodes and activated T cells via afferent lymphatics [30]. 
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Considering this evidence, we analyzed if indirect co-culture of CD8+ T cells during their activation 
with live skin explants and gut organoids, containing live epithelia, promotes or inhibits PI16 
expression. We found that co-culture of CD8+ T cells with skin explants provided some support for 
the induction of a skin-homing phenotype in terms of CLA and CCR8 expression, partly in an 
activation-dependent manner (Fig 6D). However, PI16 expression was not promoted by co-
cultivation with skin explants (Fig 6D, Two-Way RM ANOVA, p>0.05). Also, expression of PI16 
remained unaffected by the presence of intestinal organoids (Fig 5E Two-Way RM ANOVA, p>0.05). 
Hence, induction of PI16 on skin-homing CD8+ T cells seems to be independent of known factors 
inducing other skin-homing CD8+ T cell biomarkers, and particularly those affecting CLA expression. 
Skin-committed CD8+ T cells maintain PI16 expression until their activation  
As PI16-expression was most typical for skin-homing, non-naïve, memory-like CD45RO+/CD8+ T cells 
(Fig 3C), and stimulation of peripheral PI16+ T cells resulted in rapid downregulation of this marker 
(Fig 6C), we next tested whether re-activation of memory-like T cells leads to loss of PI16. We found 
that re-activation of CD45RO+ T cells by a-CD3/CD28 led to an almost complete elimination of PI16 
from the cell surface within 48 hours (Fig 7A, Two-Way RM ANOVA, p=0.0002). In marked contrast, 
PI16 was barely present on bona fide naïve CD45RO-/CD8+ T cells, and did not react to activation 
either (Fig 7A). Next we tested the mechanism of PI16 removal from the surface of re-activated skin-
homing memory-like CD8+ T cells. Considering i) that bacterial PLC was capable of detaching PI16 
from the surface of skin-homing T cells and ii) that PLC activation is an inherent component of T cell 
activation, we hypothesized that activation of the PLC pathway in T cells may be responsible for the 
removal of PI16 from the cell surface upon activation. Hence, we tested whether i) inhibition of PLC 
activity by U-73122, ii) inhibition of the angiotensin-converting enzyme, another possible GPI-
removing enzyme by captopril, [31, 32], or iii) inhibition of possible endocytic recycling of PI16 by 
Dynasore could inhibit loss of PI16 from the cell surface upon activation. We observed that loss of 
PI16 upon a-CD3/28 treatment could not be inhibited by PLC- or ACE-inhibitors, or by stopping 
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endocytic protein recycling either (Fig 7B). On the other hand, we found that skin-homing CD8+ T 
cells ceased to express PI16 mRNA post activation, closely followed by the loss of the protein from 
the plasma membrane (Fig 7C). Overall, these data suggest that re-activated skin-committed CD8+ 
memory-like T cells lose PM-bound PI16 by transcriptional downregulation, and not due to protein 
shedding or increased recycling of the protein from the PM. 
PI16 acts as a partial inhibitor of cathepsin K  
Typically, re-activation of CD8+/CLA+/CD45RO+, skin-homing memory T cells occurs within the 
human skin, where  a large number of proteases, involved in various inflammatory processes and 
pathologies, are present [Reviewed in:33, 34]. Considering that PI16 is a largely unknown, rather 
putative, peptidase inhibitor, we tested whether human PI16 was capable of suppressing the activity 
of skin proteases. Earlier it was suggested that mouse PI16 may suppress murine cathepsin K [27], 
and that PI16 may inhibit MMP-2 [35]. Our protease inhibitor assays (Fig 8) demonstrated that, in 
line with others’ mouse data, human PI16 is a partial inhibitor of human cathepsin-K (Fig 8A). Human 
PI16 has an IC50 comparable to synthetic inhibitors, but in line with others’ findings made in a murine 
system, it is not able to achieve full enzymatic inhibition [27]. On the other hand, at least in our 
hands, human PI16 did not affect human MMP-2 activity (Fig 8B). To further corroborate these 
findings, and also to identify other skin proteases possibly interacting with PI16, we next performed 
pull-down assays utilizing PI16 as a bait to find its partners in human skin protein lysates. 
Comparative analysis of the flow-through and the pulled down protein fractions showed that PI16 
did not display high affinity against a large number of skin proteases, i.e. cathepsins A, D, V, X, Z, P, 
kallikreins 5, 10, 11, CD26 (dipeptidyl peptidase-4), and MMP-2 (Fig 8C), as none of them were 
specifically enriched in the pulled-down fraction, or depleted from the flow-through by PI16. Taken 
together, these data suggest that human PI16 on skin-homing T cells may act as a partial inhibitor of 
cathepsin K in the human skin, but may not bind to other skin proteases with high affinity.         
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Discussion 
This study shows that by analyzing human patients diagnosed with aGvHD, further insight may be 
gained into the mechanisms regulating cutaneous and gastrointestinal CD8+ T cell homing. Our data 
suggest that peptidase inhibitor 16 (PI16) is a novel protein marker displaying robust association 
with the skin-homing CD8+ T cell phenotype in both health and disease.  
PI16 was first described as a protein released into the blood serum by prostate cells, and originally 
designated as prostate secretory protein 94-binding protein (PSBP) due to its high affinity for PSP94 
[26]. It soon became clear that PI16 was expressed by multiple other, unrelated cell types, too, and 
the protein became incorporated into the CAP (cysteine-rich secretory proteins, antigen 5, and 
pathogenesis-related 1 proteins) superfamily [36]. All CAP proteins feature a highly conserved CAP 
domain, but they are rather heterogeneous due to additional, highly variable protein domains, 
which allow them to exert multiple, independent biological functions. These include involvement of 
CAP proteins into endocrine and paracrine regulation, regulation of matrix reorganization, but also 
fertilization, signaling, immunomodulation and host defense.  
Nevertheless, the function of the highly conserved core domain, the CAP domain itself is poorly 
understood, and hence the common function of such proteins is still a matter of speculation[37]. 
This issue becomes critical in the case of PI16, as it consists of nothing but the signature CAP domain 
and a rather long hinge region. Without solid knowledge on the function of CAP domains, 
deciphering the function(s) of PI16 remains challenging. In this regard, the hinge region itself is not 
particularly helpful either, as it lacks similarity to any known protein domains. Even though its very 
end is rich in hydrophobic amino acids, it has no confirmed intramembrane or intracellular domains 
[36]. Based on sequence analysis of the hinge, existence of a GPI anchor attached to the end of PI16 
has been first suspected [26], then confirmed, in mice [27], but so far, not in humans. Based on 
sequence homology, PI16 was hypothesized to act as a protease inhibitor, and in line with this, it has 
been proposed that PI16 suppresses cathepsin K [27], and MMP-2 activity [35]. So far, these 
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activities have only been shown by studying murine cardiomyocytes and human cardiac 
endothelium, respectively, and have not been confirmed in humans or by independent research 
groups. To sum up, the exact biological roles and the functional properties of the CAP domain, most 
CAP family members, also including PI16, have, until now, remained largely obscure[36, 37].  
This study demonstrates that human skin-homing CD8+ T cells display a GPI-anchored, PM-bound 
form of PI16, and that PI16 expression is most pronounced in the CD45RO+ memory compartment. 
Interestingly, earlier observations of others have already provided some, albeit very circumstantial, 
evidence supporting the notion that PI16 may be linked to cutaneous homing of T cells. Among the 
extremely limited number of papers published on PI16, one has shown that PI16 is expressed by 
Tregs responding to CCL17 [22]. This is relevant to our findings because CCL17 is recognized by CCR4, 
which is a chemokine receptor on many skin-homing T cells. There is a large body of evidence 
confirming the involvement of CCL17 and CCR4 homing of T cells to the skin, especially under 
inflammatory conditions [38, 39], and mostly within the non-naïve (effector/memory) T cell 
compartment [40]. Further corroborating this concept, in another paper, a genome-wide association 
study identified a polymorphism within the PI16 gene that predisposed to chronic skin inflammation 
[21].  
We found that in healthy blood donors, the majority of CD8+/CLA+ T cells expressed PI16, which was 
in sharp contrast with the scarce PI16 positivity observed on other, CD8+/CLA- T cell subsets. 
However, expression of PI16 was neither complete within the skin-homing T cell subset, nor was it 
exclusive to the skin-homing phenotype. In short, PI16 is clearly associated to T cell homing, but it 
has limited sensitivity and specificity as a marker of all skin-homing T cells. We found that PI16 
expression was most characteristic for non-naïve CD45RO+, memory-like skin-homing CD8+ T cells, 
and was less typical for recently activated (CD69+, Granzyme B+) effector cells homing to the skin. In 
addition, expression of PI16 was tightly controlled, and became virtually eliminated by CD45RO+ 
CD8+ T cells upon their re-activation in vitro. Collectively, these data suggest that within the non-
 This article is protected by copyright. All rights reserved. 13 
naïve CD8+ T cell compartment, PI16 expression may be less typical for recently activated, or re-
activated cells exerting effector functions. Interestingly, differences in PI16 expression in health and 
disease also suggested that PI16 expression became less pronounced once skin-homing T cells had 
been activated. As judged by flow cytometry, PI16 expression of skin-homing CD8+ T cells was most 
prominent in healthy blood donors (having limited numbers of activated skin-homing CD8+ T cells), 
was less pronounced in aGvHD (polyclonal CD8+ T cell activation), and was even less prominent in 
active cutaneous aGvHD (widespread activation of  skin-homing CD8+ T cells).   
We also showed that PI16 disappeared from activated CD8+ T cells by means of transcriptional 
downregulation, and not by GPI anchor digestion and subsequent protein shedding. These 
observations may allow speculation that the PI16 function(s) associated to skin-homing T cells are 
not related to release of this putative peptidase inhibitor into the extracellular space. They rather 
suggest that the function(s) of PI16 become(s) either dispensable or detrimental upon cognate 
activation of skin-homing CD8+ T cells in the skin, e.g. in cutaneous immune responses requiring 
local CTL intervention.  
In this regard, it is interesting that both MMP-2 and cathepsin K, the two proposed targets of PI16 
action, are critically involved in the regulation of skin tissue homeostasis. MMP-2 is an extracellular 
protease the altered activity of which has sweeping consequences for the skin; MMP2 alters both 
the availability and activity of a plethora of signaling ligands and adhesion molecules affecting 
cutaneous integrity and local inflammation [41]. Cathepsin K, on the other hand, being capable of 
collagen and elastin digestion, is also linked to skin inflammation, matrix reorganization and scar 
formation both as an intracellular lysosomal enzyme [42], and as a secreted, extracellular protease 
[43]. We found that similar to murine data, human PI16 was capable of interfering with human 
cathepsin K activity, acting as a partial inhibitor in the submicromolar range. However, in our hands, 
recombinant PI16 was not able to suppress MMP-2 activity or pull-down MMP-2 from skin lysates, 
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which conflicts others’ observations and hence the role of PI16 as a regulator of MMP-2 will need 
further analysis.  
Taken together, our data indicate that resting human skin-homing CD8+ T cells are instructed to 
display PI16, and maintain its expression until their re-activation. The possibility that re-activation of 
skin-committed CD8+ CLA+ T cells may suppress an inhibitor (PI16) of a cutaneous inflammatory 
protease (cathepsin-k) is intriguing. This observation may allow speculation that during T cell-
mediated cutaneous immune responses, cutaneous CD8+ T cells may affect skin homeostasis by 
stopping inhibition of select inflammatory proteases. Nevertheless, a more complete understanding 
of the role of PI16 in this context needs further studies, particularly studies focusing on the exact 
function of the CAP domain, the signature structural component of this elusive peptidase inhibitor.   
Materials & Methods 
Tissues 
Human skin and intestinal biopsies were obtained from patients of the Department of Dermatology, 
Venereology and Dermatooncology, Budapest, Hungary, and the Uzsoki Hospital of the Semmelweis 
University, Budapest, Hungary, respectively. Biopsies were retrieved following IRB approved 
protocols, after obtaining informed consent from all involved patients. Sections of biopsies used 
were evaluated by pathologists and declared disease-free.   
Blood samples 
Blood samples were collected from selected allo-HSCT patients (n=20, see Supplementary Table I) of 
the Dept. of Hematology and Stem Cell Transplantation, St. Istvan and St Laszlo Hospital, Budapest, 
Hungary for research purposes, after obtaining informed consent and IRB approval. Allo-HSCT 
patients belonging to the following groups were recruited: i) patients developing no acute GvHD 
following allo-HSCT, ii) allo-HSCT patients with acute cutaneous GvHD, iii) allo-HSCT patients with 
acute gastrointestinal GvHD, or iv) allo-HSCT patients with both acute and gastrointestinal aGvHD 
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(see Supplementary Table 1 for details, n=5 each). Samples from allo-HSCT patients without acute 
GvHD were collected after ca. 30 days post allo-HSCT (no-GvHD group). Samples from allo-HSCT 
patients with aGvHD were collected at the time of diagnosis, before any GvHD-specific treatment 
had been commenced (GvHD groups). In addition, control blood samples were also collected from 
healthy volunteers, as well (n=10).  
PBMC isolation 
Peripheral blood was collected by venipuncture in VACUETTE® Acid Citrate Dextrose (ACD-A) tubes 
(BD). Samples were stored and transported at RT. PBMCs were isolated by density centrifugation 
using Histopaque-1077 (Sigma-Aldrich) over LeucoSep™ centrifuge tubes (Greiner Bio-One). Median 
PBMC yield was 1.3x106 PBMC/ml blood; cell viability was > 95% by trypan blue exclusion. Within 
2.5+/-0.5 hours of venipuncture, cells were frozen in 90% FBS/10% DMSO using a Mr. Frosty freezing 
container (Thermo) at –80C and transferred to liquid nitrogen until further use. 
FACS sorting  
FACS sorting was used to isolate skin- and gut-homing CD8+ T cells for microarray gene expression 
profiling. Frozen PBMC samples were thawed as described elsewhere [44] and immediately stained 
with LIVE/DEAD® Fixable Dead Cell Stain Near-IR (Thermo), anti-human CD8β-APC, anti-human 
Cutaneous Lymphocyte Antigen (CLA)-FITC, and anti-human Integrin β7 (ITGβ7)-PE antibodies (all 
from BD). Three-way sorting of PBMCs was done on a BD FACSAria III sorter. Skin-homing 
Ly/LIVE/DEAD®-/CD8β+/CLA+ T cells, gut-homing Ly/LIVE/DEAD®-/CD8β+/ ITGβ7+ T cells, and 
Ly/LIVE/DEAD®-/CD8β+/CLA-/ITGβ7- T cells, the latter serving as reference, were acquired with the 
help of the FACSDiva software (BD). Viability of sorted T cells was >95% by LIVE/DEAD® staining. T 
cells were sorted directly into RLT Plus lysis buffer (Qiagen); and the cell lysates were subsequently 
frozen at -80C.  
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Microarray gene expression profiling 
Total RNA was extracted from FACS-sorted CD8+ T cell subsets using the RNeasy Plus Micro Kit 
(Qiagen). Sample integrity and yield were assessed on a 2100 Bioanalyzer using an RNA 6000 Pico Kit 
(Agilent). Three-thousand pg total RNA per sample was amplified in two rounds and Cy3-labeled by 
the Arcturus RiboAmp HS PLUS, Cy3 labeling Kit (Thermo). Cy3-labeled amplified cRNA was 
hybridized to human GE 4x44K v2 whole-genome microarrays (Agilent) and scanned on an Agilent 
Microarray Scanner. Raw data were retrieved with the Feature Extraction software (Agilent). Batch 
effect was removed by distance weighted discrimination [45]. Analyzes were performed using the 
BRB-ArrayTools developed by Dr. Richard Simon and the BRB-ArrayTools Development Team. The 
following genes were excluded from further analyzes: genes flagged as not detected, genes 
displaying batch adjusted signal intensities lower than log2=1, genes not detected in all samples of 
any experimental groups, and genes not displaying 2-fold change in at least one experimental group 
in either direction from the given gene’s median value. The remaining gene set (1,981 genes) was 
analyzed by Two-way repeated measures ANOVA and Benjamini-Hochberg multiple testing 
correction (FDR<0.01) to identify differentially expressed genes (DEGs). Microarray data have been 
deposited at GEO under accession number GSE103569. 
Q-PCR 
Total RNA was extracted and reverse transcribed from FACS-sorted T cell subsets as above. PI16 
gene expression was assessed with human PI16-specific TaqMan probes and HGPRT as internal 
reference. cDNA was amplified on a 7900HT Fast Real-Time PCR machine (Thermo) using 2x Sensifast 
Probe HI-ROX master mix (Bioline, Taunton, MA). Results were calculated using the comparative CT 
(ΔΔCT) method. 
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Flow cytometry 
For flow cytometry, cells were stained with anti-human CLA-FITC, IFN-γ-FITC, Integrinβ7-PE, PI16-PE, 
CCR10–PE, CCR4–PE, CCR8-PE, CD8β–APC, CD8β-PECy7, CD3-APC, CD59-FITC, CD14 PerCP-Cy5.5, 
CD56-APC (BD), granzyme-B–FITC, CD69–FITC (Biolegend), CD127–FITC, CD25–PerCP-eFluor710, 
CD45RO PerCP-eFluor710 (Thermo), anti-human PI16-APC antibodies (Miltenyi Biotec) and 
appropriate isotype controls  following standard protocols, as indicated. Intracellular antigens were 
stained using Brefeldin-A and Fixation/Permeabilization Solution (BD). Cells were analyzed on a 
FACSCalibur flow cytometer (BD). Data were evaluated using the FlowJo v10.1 software (Treestar).   
MACS sorting 
MACS sorting was applied for all CD8+ T cell studies other than gene expression profiling. CD8+ T 
cells were isolated from PBMCs of healthy blood donors using anti-human CD8β APC antibodies (BD) 
and anti-APC multisort microbeads. Magnetic cell sorting was done on an AutoMACS Pro cell sorter, 
using the posselds program (Miltenyi Biotec). APC-multisort microbeads were released from sorted 
cells before any downstream assays have been commenced with. 
Immunocytochemistry 
MACS-sorted CD8β+ T cells were blocked with mouse and rat sera (Sigma-Aldrich) and stained with 
anti-human CLA–FITC, PI16–PE and CD8β-APC antibodies (BD). For APC detection, signal 
amplification was done using anti-APC-biotin and Streptavidin-APC (Biolegend). After staining, 
cytospin slides were prepared, and samples were covered with Fluoroshield, with DAPI histology 
mounting media (Sigma-Aldrich) overnight, at room temperature (RT). Images were taken on an 
FV500 inverted laser scanning confocal microscope (Olympus) at 60x magnification. Image analysis 
was performed with the Image J v. 1.8.0_112  software. 
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Immunohistochemistry 
FFPE tissue sections (5µm) were prepared from healthy human skin biopsies. Antigen retrieval was 
done in sodium citrate buffer (pH=6.0) at ~+105 °C for 30 min. Samples were blocked with 10% FBS 
and stained with rat anti-human CLA-FITC (1:10, BD), mouse anti-human CD8a (1:50, Santa Cruz) and 
rabbit anti-human PI16 (1:100, Novus) antibodies. Secondary antibodies used were anti-mouse IgG-
eFluor570 (1:100 eBioScience), and anti-rabbit IgG-APC (1:100, Thermo). Staining controls were done 
by omitting primary antibodies. Images were captured with an inverted confocal microscope 
(Olympus FV500) at 20× magnification and evaluated with Image J v. 1.8.0_112. 
GPI anchor digestion 
MACS-sorted CD8β+ T cells were washed twice with PBS, and 1x106 cells/500 ul were left untreated 
or exposed to various doses of B. cereus PI-PLC (Thermo), as indicated, for 1 hour at RT. Cells were 
immediately stained and analyzed by flow cytometry, as indicated.  
Retinoic acid and 1,25-dihydroxivitamin D3 treatment   
MACS-sorted CD8β+ T cells were seeded on 24 well plates at a density of 7 x 105 cells/well, in 
glutamine-supplemented RPMI 1640 (Thermo), 10% human serum type AB, 1x Glutamax, 1% 
penicillin/streptomycin (Sigma-Aldrich). Culture media and sera were pretested for assay 
performance in pilot studies. Cells were activated with Dynabeads CD3/CD28 (Thermo) at a cell:bead 
ratio of 1:3 for 2 days in the presence of 2.5ng/ml recombinant human IL-12 (Thermo). After 2 days, 
cultures were supplemented with recombinant 12.5 ng/ml IL-2 (Thermo), split into three and treated 
with 10-8M retinoic acid (RA), 10-8M 1,25-dihydroxivitamin D3 (D3) (Sigma-Aldrich), or vehicle only 
(0.1 % ethanol). Every two days till day 10 post activation, cultures were split into two, 
supplemented with fresh chemicals and media, and analyzed by flow cytometry. 
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Co-culture of activated CD8+ T cells with skin explants and intestinal organoids  
CD8+ T cell isolates were obtained and activated as above, and maintained in the lower chambers of 
24 well 0.4 um pore size transwell plates. CD8+ T cells obtained from a single donor were split in 
four, and were either i) left untreated, ii) activated only, iii) co-cultivated with explants/organoids 
only, or iv) activated and also co-cultured with explants/organoids. For CD8+ T cell co-culture with 
skin explant cultures, healthy skin biopsies were cut into 3-4 pieces and transferred to the upper 
chamber of the transwell plates on day 2. Fifty µL of RPMI 1640 (Thermo), 10% human serum type 
AB, 1% pen/strep (Sigma-Aldrich) were added to the upper chamber of each well, and skin biopsies 
were maintained at the air-liquid interphase for 4 further days. For CD8+ T cell co-culture with 
intestinal organoids, healthy colon samples were processed as described elsewhere [46], with minor 
modifications. Briefly, colonic crypts were isolated by resuspension of colon biopsies with a cold 2 
mM EDTA release buffer. Isolated crypts were embedded in 40 µL matrigel (Corning) and transferred 
to the upper chamber of transwell plates as above. After the matrigel sealed the chamber, 400 
µL/well culture medium, consisting of Advanced DMEM/F-12, 5% FBS, 1x Glutamax, 1× N-2, 1× B-27 
(all from Thermo), 10 mM HEPES, pen/strep, 1 mM acetylcysteine, 500 nM A-83-01, 10 µM 
SB202190, 10 nM [Leu15]-Gastrin I (all from Sigma-Aldrich) 50 ng/ml hr EGF, 100 ng/ml h noggin, 
100 ng/ml mr Wnt3A (all from Peprotech), and 500 ng/ml h R-Spondin1 (R&D) was added on top of 
the solidified matrigel, and organoids were maintained for 4 further days. Every 2 days till day 4 post 
activation, explant/organoid media was replaced, T cell cultures were split into two, supplemented 
with fresh chemicals and media, and analyzed by flow cytometry.  
Pulldown assay and proteome profiling 
Human skin samples, obtained as above, were immediately transferred to a ProteoJet Mammalian 
Cell Lysis Reagent, (Thermo) supplemented with Halt™ Protease Inhibitors Cocktail (Thermo) and 
pre-incubated at +4Co for 30 mins. Next, subcutaneous fat was removed, samples were cut in 1-3 
mm pieces by sterile scalpels and homogenized with a Diax 100 homogenizer (Heidolph). Debris 
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were removed by centrifugation. Skin lysates were stored at -80C until further use. For protein 
pulldown, 10 µg recombinant GST-tagged human PI16 (Abnova) was dialyzed using Slide-A-Lyzer™ 
Dialysis Cassettes (Thermo). After removal of excess glutathione, PI16 was bound to glutathione-
linked agarose beads of the Pierce™ GST Protein Interaction Pull-Down Kit (Thermo). Pull-down 
assay was performed with 100 µg skin protein lysate, following the manufacturer’s instructions. 
Proteome profiling was used to compare the following fractions in a pair-wise manner: i) specific 
pull-down fraction (PI16-bound agarose beads), ii) aspecific binding control (empty agarose beads), 
iii) whole skin lysate before pulldown, iv)  flow-through fraction after pull-down. Skin proteases 
specifically bound to PI-16 in pull-down assays were identified using Proteome Profiler™ Human 
Protease Array Kits (R&D). PI16-bound skin proteases were identified by comparing the specific pull-
down fraction with the aspecific binding control, and the whole skin lysate with the flow-through, 
respectively. Sample preparation, membrane incubation, and signal detection were all carried out 
following the manufacturer’s instructions. Densitometry was done using the FluorChem Alphaview 
software (Alpha Innotech).  
Protease inhibitor assays 
Protease inhibitor assays were carried out using 25 µg recombinant GST-tagged human PI16 
(Abnova) protein, pre-dialyzed on Slide-A-Lyzer™ Dialysis Cassettes (Thermo). Various dilutions of 
dialyzed PI16 peptide, as indicated, were tested as putative inhibitors of cathepsin K and MMP-2 
using a Cathepsin K Inhibitor Screening Kit and an MMP2 Inhibitor Screening Assay Kit, respectively 
(both from Abcam, Cambridge, UK). Assays were done in duplicates, following the manufacturer’s 
instructions. Cathepsin K assays were evaluated on a Labsystems Luminoskan reader (Thermo). 
Results of MMP-2 assays were obtained using a Labsystems Multiskan MS spectrophotometer 
(Thermo). 
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Statistical analysis 
Statistical analysis was done using BRB Array Tools (microarray results) or the Graphpad software (all 
other analyses). Two-way repeated measures (RM) ANOVA, one-way repeated measures (RM) 
ANOVA and paired t-tests were used together with Benjamini-Hochberg false discovery rate (FDR)-
correction for multiple testing and pairwise comparisons, as needed. Unless otherwise stated, 
p<0.05 (t-tests) or FDR <0.05 (all other tests) was considered statistically significant. 
General laboratory operation and raw data accessibility 
These studies were conducted in an ISO 9001:2015-certified laboratory that operates under 
exploratory research principles. All studies were performed using standard operating protocols and 
research assays. FACS sorting and flow cytometry was performed following the ‘Guidelines for the 
use of flow cytometry and cell sorting in immunological studies’[47]. Methodology and results of T-
cell assays were described in accordance with the MIATA guidelines [48]. Raw data can be provided 
per request.  
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Figure legends 
 
Fig. 1  
Comparative gene expression profiling of skin-homing, gut-homing, and reference CD8+ T cells of 
aHSCT patients developing no aGvHD, cutaneous aGvHD, gastrointestinal GvHD, or both aGvHD 
manifestations simultaneously.  (A) Gating strategy and representative three-way FACS-sorting of 
gut-homing Ly/Live/CD8/ITG7+, skin-homing Ly/Live/CD8/CLA+, and reference 
Ly/Live/CD8/ITG7-/CLA- cytotoxic T cells, isolated from PBMCs of aHSCT patients. Numbers 
indicate percent gated cells. One experiment representative of five independent experiments with 
n=4 donors for each group, n=20 donors total. (B) FACS-sorted gut-homing, skin-homing and 
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reference cytotoxic T cells (as indicated at the top) of aHSCT patients developing no aGvHD, 
cutaneous aGvHD, intestinal aGvHD, or both aGVHD manifestations simultaneously (as indicated at 
the bottom), analyzed by gene expression profiling (n=5 for each possible T cell subset/disease group 
combination). Heatmap displays 62 differentially expressed genes, identified by Two-Way RM 
ANOVA (FDR<0.01), analyzing sources of variance introduced by CD8+ T cell homing subsets, 
respective organ damage, and possible interactions between these two factors. Columns represent 
individual samples; rows correspond to genes. Colors display expression below (pale blue), or above 
(dark blue) the mean. For clarity’s sake, data shown are centered and SD-normalized. To the right, 
asterisk marks peptidase inhibitor 16 (PI16). Combined results of three independent experiments 
with n=4, n=8, and n=8 donors for each group, n=20 total. 
 
Fig. 2. Testing the link between PI16, CD8+ T cell homing subsets, and aGvHD organ involvement 
by microarray gene expression profiling, Q-PCR, and flow cytometry. (A, C, and E (top)) PI16 
expression in skin-homing CD8/CLA+, gut-homing CD8/ITG7+, and reference CD8/ITG7-/CLA- 
cytotoxic T cells of aHSCT patients, as analyzed by microarray, Q-PCR and flow cytometry, 
respectively (n=15 each, median) is shown. One-way RM ANOVA with FDR correction; stars indicate 
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significance in pairwise comparisons: ***p<0.001 (B, D and F (bottom)) PI16 expression among the 
same three cytotoxic T cell subsets, also accounting for possible differences introduced by CD8+ T 
cell-mediated organ damage, i.e. in patients with no aGvHD, cutaneous aGvHD, intestinal aGvHD, or 
both manifestations of aGvHD.  (n=5 for each possible T cell subset/disease group combination; box 
and whiskers plots with median). Two-way RM ANOVA with FDR correction; stars indicate 
significance in pairwise comparisons: * p<0.05, ** p<0.01, ***p<0.001. ( G (far right) Representative 
flow cytometry data of a single patient. Numbers indicate percent gated cells. Combined results of 
three experiments with n=4, n=8, and n=8 donors for each group, n=20 total. 
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Fig. 3. Evaluation of PI16 as a marker associated with skin-homing CLA+ T cells of healthy 
individuals.   
(A) Frequency of PI16 positive cells among skin-homing CD8/CLA+, gut-homing CD8/ITG7+, and 
reference CD8/ITG7-/CLA- cytotoxic T cells of healthy blood donors. Gating strategy and 
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representative data for each analyzed cytotoxic T cell subset are shown to the left. One-way RM 
ANOVA with FDR correction is shown to the right (one experiment, n=7, median): stars indicate 
significance in pairwise comparisons: ***p<0.001. (B) PI16 expression in distinct PBMC subsets 
expressing the canonical skin-homing T cell marker CLA; typical patterns of PI16 expression in 
CLA+ blood cytotoxic T cells, CLA+ helper T cells, CLA+ NK cells and CLA+ monocytes of healthy 
blood donors (n=3, representative data). (C) Comparative analysis of PI16- and PI16+ skin-
homing CD8+ T cells of healthy blood donors (n=6, box and whiskers plot with median). Paired t-
test: **p<0.01 ***p<0.001. Each panel shows one experiment representative of six (panel A), or 
two (panels B and C). 
 
Fig. 4. Spatial distribution of PI16 protein and skin-resident CD8+ T cells in the skin. Analysis of the 
localization of CD8+ skin-homing T cells and PI16 in healthy human skin. (A and B) Phase contrast 
and composite fluorescent images of a representative human skin section analyzed by 
immunohistochemistry is shown. (C) Selected regions of (B) sections I-II represent dermal, sections 
III-IV epidermal staining with DAPI, CD8-, CLA-, and PI16-specific antibodies, as indicated. Shown are 
results of one experiment representative of four, one sample each.    
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Fig. 5. Analysis of the sub-cellular distribution of PI16 protein in skin-homing CD8+ T cells . (A) 
Analysis of the sub-cellular localization of PI16 in skin-homing CD8+ T cells. Phase contrast, 
monochrome and three-color fluorescent microscopy of MACS-sorted CD8+ T cells is shown. Blue: 
CD8, green: CLA red: PI16. Representative sub-cellular distribution of PI16 in a typical, skin homing, 
CD8+/CLA+/PI16+ T cell is displayed in the cell at the center. One experiment representative of 
three independent experiments.  (B) Investigation of human PI16 as a possible GPI-anchored PM 
protein of T cells. Assessing cell surface PI16 signal after PI-PLC-mediated in vitro digestion of GPI-
anchors. CD59 (a known GPI-anchored PM protein) and CD8 (having no GPI anchor) serve as 
positive and negative controls, respectively. Numbers indicate percent positivity of T cells upon 
exposure to various concentrations of PI-PLC, as shown. One experiment representative of two 
independent experiments. 
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Fig. 6. Investigation of the induction of PI16 expression in skin-homing CD8+ T cells. (A-C) Impact 
of vitamin D3 (D3) and retinoic acid (RA) treatment on the expression of the canonical skin-homing 
markers CLA (panel A) and CCR10 (panel B), versus on that of PI16 (panel C) after ex vivo activation 
of peripheral blood CD8+ T cells with aCD3/28 (n=3, mean with SEM). Gating strategy and 
representative results obtained on days 0 and day 4 are shown below. Results of one experiment 
representative of two experiments. (D) Expression of skin-homing markers CLA and CCR8, and that 
of PI16 on activated CD8+ T cells after 4 days long co-culture with skin organoids (n=3, mean with 
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SEM) One experiment representative of two. (E) Expression of CLA, the gut-homing marker integrin 
7 (ITG7) and PI16 on activated CD8+ T cells upon 4 days of co-culture with gut organoids (n=3, 
mean with SEM). One experiment performed. For clarity, all bar charts display % PI16 positivity 
compared to day 0 untreated controls as reference. Results of FDR-corrected Two-way RM ANOVA 
are shown with stars indicating significance in pairwise comparisons: * p<0.05, ** p<0.01, 
***p<0.001.  
 
Fig. 7. Analysis of the termination of PI16 expression in skin-homing CD8+/CD45RO+ T cells. (A) 
PI16 protein expression of healthy blood donors’ CD8+/CD45RO+ and CD8+/CD45RO- T cells 
before, and at various time points after ex vivo activation by anti-CD3/CD28 (n=3, mean with SEM). 
Two-way RM ANOVA with FDR correction: * p<0.05, ** p<0.01, ***p<0.001 in pairwise comparisons. 
(B) Flow cytometry analyzing PI16 expression upon anti-CD3/CD28 treatment in the absence and 
presence of U-73122 (inhibitor of PLC-mediated shedding of GPI-anchored proteins), captopril 
(inhibition of ACE-mediated shedding), or Dynasore (inhibition of endocytic protein recycling, n=3; 
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mean with SEM). (C) Kinetics of PI16 mRNA expression upon a-CD3/28-mediated activation of CD8+ 
T cells as assessed by Q-PCR (n=3, mean with SEM). FDR-corrected One-way RM ANOVA: in pairwise 
analyses, stars indicate significance: ** p<0.01. Each data set represents one experiment of two 
performed. 
 
Fig. 8. Testing human PI16 as an inhibitor of human matrix metalloprotease-2, cathepsin K, and 
other skin proteases involved in skin homeostasis and cutaneous inflammation. (A and B) Relative 
activity of human cathepsin K (CTSK) and matrix metalloprotease-2 (MMP-2), respectively, in the 
presence of various concentrations of potent synthetic inhibitors and recombinant human PI16. Half-
maximal inhibitory concentration (IC50), calculated by nonlinear regression, is shown in log10M 
concentration. Shown are the results of one experiment out of two for both CTSK and MMP-2, each 
data point representing a mean of duplicates. (C) Pull-down assay utilizing PI16-covered beads as 
baits, and PI16-free beads as controls performed to identify other human skin proteases selectively 
binding to recombinant human PI16. Distribution of various skin proteases in the pull-down vs. the 
flow-through fractions in both cases, as analyzed by proteome profiling arrays. One experiment 
representative of two, one sample each. 
